Nautilus Biotechnology Inc. is a pre-commercial life sciences company focused on revolutionizing the field of proteomics. Founded in 2016, the company is developing the Nautilus Voyager platform, an end-to-end solution comprising proprietary instruments, reagent kits, consumables, and software analysis tools. The platform utilizes a novel Iterative Mapping method and high-definition optical imaging to enable large-scale, single-molecule protein quantification. By providing extreme sensitivity and scale, Nautilus aims to democratize access to the proteome, allowing researchers to measure proteins more deeply and consistently than traditional laboratory methods. Currently in the development stage, Nautilus does not yet generate product revenue and is focused on advancing its technology toward a planned commercial launch. The company targets a broad customer base, including academic and research institutions, biopharmaceutical companies, and clinical diagnostics labs, to support applications in drug discovery, biomarker identification, and precision medicine. Nautilus operates primarily out of its corporate headquarters in Seattle, Washington, and its research and development facility in San Carlos, California. The company has established strategic research collaborations with prominent institutions such as Genentech, the Allen Institute, and the Michael J. Fox Foundation to validate and refine its proteomics platform ahead of its commercial rollout.
